Does the media favor DSGN or HRTX?

In the previous week, Heron Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Heron Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Heron Therapeutics' score of -0.38 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TLRY or HRTX?

In the previous week, Tilray Brands had 17 more articles in the media than Heron Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 3 mentions for Heron Therapeutics. Tilray Brands' average media sentiment score of 0.54 beat Heron Therapeutics' score of -0.38 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 5 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HRTX or PRME?

In the previous week, Prime Medicine had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Prime Medicine and 3 mentions for Heron Therapeutics. Prime Medicine's average media sentiment score of 0.62 beat Heron Therapeutics' score of -0.38 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRS or HRTX?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 3 mentions for Heron Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.97 beat Heron Therapeutics' score of -0.38 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLYM or HRTX?

In the previous week, Climb Bio had 8 more articles in the media than Heron Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 3 mentions for Heron Therapeutics. Climb Bio's average media sentiment score of 0.51 beat Heron Therapeutics' score of -0.38 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Heron Therapeutics (HRTX) Competitors

$0.40 -0.01 (-1.43%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.41 +0.01 (+1.47%)

As of 06/12/2026 07:52 PM Eastern

Compare

HRTX vs. DSGN, TLRY, PRME, ACRS, and CLYM

Should you buy Heron Therapeutics stock or one of its competitors? MarketBeat compares Heron Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heron Therapeutics include Design Therapeutics (DSGN), Tilray Brands (TLRY), Prime Medicine (PRME), Aclaris Therapeutics (ACRS), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.

How does Heron Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Heron Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Heron Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Heron Therapeutics' score of -0.38 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Heron Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A

Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Design Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 50.41%. Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 524.84%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Design Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Design Therapeutics' return on equity of -33.07% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Summary

Design Therapeutics and Heron Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Tilray Brands has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Heron Therapeutics has a net margin of -20.53% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Tilray Brands presently has a consensus price target of $11.50, suggesting a potential upside of 130.92%. Heron Therapeutics has a consensus price target of $2.50, suggesting a potential upside of 524.84%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tilray Brands had 17 more articles in the media than Heron Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 3 mentions for Heron Therapeutics. Tilray Brands' average media sentiment score of 0.54 beat Heron Therapeutics' score of -0.38 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	5 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heron Therapeutics has lower revenue, but higher earnings than Tilray Brands. Heron Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Tilray Brands beats Heron Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Prime Medicine?

Heron Therapeutics (NASDAQ:HRTX) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Heron Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A
Prime Medicine	$4.63M	108.45	-$201.14M	-$1.23	N/A

Heron Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Heron Therapeutics currently has a consensus target price of $2.50, suggesting a potential upside of 524.84%. Prime Medicine has a consensus target price of $7.65, suggesting a potential upside of 175.18%. Given Heron Therapeutics' higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Heron Therapeutics has a net margin of -20.53% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

In the previous week, Prime Medicine had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Prime Medicine and 3 mentions for Heron Therapeutics. Prime Medicine's average media sentiment score of 0.62 beat Heron Therapeutics' score of -0.38 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Prime Medicine beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Heron Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.05	-$64.92M	-$0.56	N/A
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A

Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 166.20%. Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 524.84%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Heron Therapeutics has a net margin of -20.53% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 3 mentions for Heron Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.97 beat Heron Therapeutics' score of -0.38 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Heron Therapeutics beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Climb Bio presently has a consensus target price of $21.73, suggesting a potential upside of 89.92%. Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 524.84%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Climb Bio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Climb Bio's return on equity of -31.45% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

In the previous week, Climb Bio had 8 more articles in the media than Heron Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 3 mentions for Heron Therapeutics. Climb Bio's average media sentiment score of 0.51 beat Heron Therapeutics' score of -0.38 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heron Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Heron Therapeutics	$154.90M	0.49	-$20.19M	-$0.18	N/A

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Summary

Heron Therapeutics beats Climb Bio on 9 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$76.83M	$2.99B	$6.75B	$12.02B
Dividend Yield	N/A	1.76%	2.66%	5.61%
P/E Ratio	-2.22	18.07	24.02	24.43
Price / Sales	0.49	302.43	510.75	109.73
Price / Cash	N/A	56.52	44.01	55.64
Price / Book	5.72	3.99	10.66	6.79
Net Income	-$20.19M	$75.85M	$3.56B	$337.66M
7 Day Performance	-6.39%	1.14%	0.87%	2.57%
1 Month Performance	-56.24%	-3.28%	0.25%	2.04%
1 Year Performance	-79.27%	22.54%	25.22%	30.28%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	1.6077 of 5 stars	$0.40 -1.4%	$2.50 +524.8%	-80.1%	$76.83M	$154.90M	N/A	300
DSGN Design Therapeutics	3.1898 of 5 stars	$10.12 -3.4%	$16.50 +63.0%	+180.6%	$654.55M	N/A	N/A	40	Positive News
TLRY Tilray Brands	3.5779 of 5 stars	$5.46 -1.0%	$11.50 +110.8%	+19.6%	$642.19M	$210.48M	N/A	2,842
PRME Prime Medicine	2.2396 of 5 stars	$3.19 -10.3%	$7.65 +140.1%	N/A	$641.19M	$4.63M	N/A	N/A	Gap Up
ACRS Aclaris Therapeutics	3.0993 of 5 stars	$4.48 -1.5%	$11.29 +151.7%	+182.4%	$635.47M	$8.37M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. DSGN, TLRY, PRME, ACRS, and CLYM

How does Heron Therapeutics compare to Design Therapeutics?

Summary

How does Heron Therapeutics compare to Tilray Brands?

Summary

How does Heron Therapeutics compare to Prime Medicine?

Summary

How does Heron Therapeutics compare to Aclaris Therapeutics?

Summary

How does Heron Therapeutics compare to Climb Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. DSGN, TLRY, PRME, ACRS, and CLYM

How does Heron Therapeutics compare to Design Therapeutics?

Does the media favor DSGN or HRTX?

Do insiders & institutionals have more ownership in DSGN or HRTX?

Which has stronger valuation & earnings, DSGN or HRTX?

Which has more risk and volatility, DSGN or HRTX?

Do analysts prefer DSGN or HRTX?

Is DSGN or HRTX more profitable?

Summary

How does Heron Therapeutics compare to Tilray Brands?

Which has more risk & volatility, TLRY or HRTX?

Is TLRY or HRTX more profitable?

Do analysts prefer TLRY or HRTX?

Does the media favor TLRY or HRTX?

Which has better earnings and valuation, TLRY or HRTX?

Do insiders and institutionals have more ownership in TLRY or HRTX?

Summary

How does Heron Therapeutics compare to Prime Medicine?

Which has preferable valuation & earnings, HRTX or PRME?

Which has more volatility and risk, HRTX or PRME?

Do analysts recommend HRTX or PRME?

Is HRTX or PRME more profitable?

Does the media refer more to HRTX or PRME?

Do institutionals & insiders hold more shares of HRTX or PRME?

Summary

How does Heron Therapeutics compare to Aclaris Therapeutics?

Which has stronger valuation and earnings, ACRS or HRTX?

Do analysts recommend ACRS or HRTX?

Which has more risk and volatility, ACRS or HRTX?

Do institutionals & insiders have more ownership in ACRS or HRTX?

Is ACRS or HRTX more profitable?

Does the media favor ACRS or HRTX?

Summary

How does Heron Therapeutics compare to Climb Bio?

Do analysts prefer CLYM or HRTX?

Is CLYM or HRTX more profitable?

Does the media prefer CLYM or HRTX?

Which has higher earnings & valuation, CLYM or HRTX?

Do institutionals and insiders hold more shares of CLYM or HRTX?

Which has more volatility and risk, CLYM or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools